

Adam C Winters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2658073/publications.pdf>

Version: 2024-02-01

17
papers

549
citations

840585

11
h-index

887953

17
g-index

19
all docs

19
docs citations

19
times ranked

831
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 126-135.	2.4	32
2	Liver Cancer Has a Distinctive Profile in Black Patients: Current Screening Guidelines May Be Inadequate. <i>Hepatology Communications</i> , 2022, 6, 8-11.	2.0	8
3	Provider Attitudes and Practices for Alcohol Screening, Treatment, and Education in Patients With Liver Disease: A Survey From the American Association for the Study of Liver Diseases Alcohol-Associated Liver Disease Special Interest Group. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2407-2416.e8.	2.4	52
4	Joining the Fight: Enhancing Alcohol Treatment Education in Hepatology. <i>Clinical Liver Disease</i> , 2021, 18, 225-229.	1.0	7
5	A Telephone and Mail Outreach Program Successfully Increases Uptake of Hepatocellular Carcinoma Surveillance. <i>Hepatology Communications</i> , 2020, 4, 825-833.	2.0	11
6	Acute Liver Failure During Pregnancy: Happy to Recover from Hep E. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2515-2517.	1.1	0
7	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2952-2961.e8.	2.4	48
8	Hepatic Encephalopathy Challenges, Burden, and Diagnostic and Therapeutic Approach. <i>Clinics in Liver Disease</i> , 2019, 23, 607-623.	1.0	20
9	A review of the use of transient elastography in the assessment of fibrosis and steatosis in the post-liver transplant patient. <i>Clinical Transplantation</i> , 2019, 33, e13700.	0.8	22
10	Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1854-1861.	0.9	11
11	The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib. <i>Case Reports in Hematology</i> , 2019, 2019, 1-3.	0.3	7
12	Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2497-2505.e1.	2.4	44
13	Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1533-1540.e2.	2.4	60
14	Reassessing the safety concerns of utilizing blood donations from patients with hemochromatosis. <i>Hepatology</i> , 2018, 67, 1150-1157.	3.6	6
15	At Diagnosis of Hepatocellular Carcinoma, African Americans With Hepatitis C Have Better Liver Function Than Other Patients. <i>Clinical Liver Disease</i> , 2018, 12, 109-112.	1.0	6
16	Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. <i>American Journal of Gastroenterology</i> , 2018, 113, 1345.	0.2	119
17	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 155, 687-695.e10.	0.6	93